KYNTRA BIO, INC. OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax
KYNTRA BIO, INC. (KYNB) reported OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax of $0 for the 6-month period ending 2021-06-30, per its 10-Q filed 2021-08-09.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax · last filed 2021-08-09
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2021-06-30 was $0.00, a 100.00% decline year-over-year.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2021-03-31 was $0.00.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-06-30 was $301.00K, a 155.08% increase year-over-year.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for the quarter ending 2020-03-31 was -$439.00K.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2018 was $0.00.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2017 was $0.00.
- KYNTRA BIO, INC. oci, debt securities, available-for-sale, gain (loss), after adjustment, tax for fiscal 2016 was -$211.00K.
| Period end | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 3 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 6 month | OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax 12 month |
|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $0.00 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $0.00 10-Q · filed 2021-05-10 | ||
| 2020-06-30 | $301.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$138.00K 10-Q · filed 2021-08-09 | |
| 2020-03-31 | -$439.00K 10-Q · filed 2021-05-10 | ||
| 2019-06-30 | $118.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | $0.00 10-Q · filed 2020-08-06 | |
| 2019-03-31 | -$118.00K 10-Q · filed 2020-05-07 | ||
| 2018-12-31 | $0.00 10-K · filed 2019-02-27 | ||
| 2018-03-31 | $0.00 10-Q · filed 2019-05-09 | ||
| 2017-12-31 | $0.00 10-K · filed 2019-02-27 | ||
| 2016-12-31 | -$211.00K 10-K · filed 2019-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |